Dr. Maria Sundvall is a distinguished physician-scientist and academic leader in Clinical Oncology and Molecular Cancer Biology, renowned for her translational research bridging laboratory discoveries with clinical applications. She earned her Medical Doctor degree in 2003, followed by a Ph.D. in Medical Biochemistry and Molecular Biology from the University of Turku, Finland, in 2007, where her thesis focused on “Signaling of ErbB4 Isoforms in Cancer.” She was later awarded the Title of Docent in 2015 and became a Specialist Physician in Clinical Oncology and Radiotherapy in 2018. Professionally, Dr. Sundvall serves as a Consultant in Clinical Oncology at Turku University Hospital and a Clinical Lecturer at the Institute of Biomedicine, University of Turku, where she also directs the Cancer Research Unit. Her earlier career includes postdoctoral research at Harvard Medical School under Professor P.P. Pandolfi, where she advanced her expertise in oncogenic signaling and targeted cancer therapies. Her research interests focus on receptor tyrosine kinase signaling, metabolic vulnerabilities in cancer, resistance mechanisms to EGFR-targeting therapies, and precision oncology for breast and prostate cancers. Dr. Sundvall possesses advanced research skills in molecular biology, cell signaling, cancer genomics, and translational medicine, with proficiency in various laboratory and clinical trial methodologies. She has authored over 34 publications in prestigious journals such as PNAS, Cancer Research, Clinical Cancer Research, and Oncogene, contributing key insights into cancer mechanisms and therapeutic resistance. Her numerous honors include the Turku University Foundation Ph.D. Thesis Award and research grants exceeding €1 million from the Research Council of Finland, the Finnish Medical Foundation, and the Sigrid Juselius Foundation. In conclusion, Dr. Sundvall exemplifies excellence in research, teaching, and clinical innovation, with her work significantly advancing the understanding of cancer biology and influencing future directions in precision oncology and patient-centered cancer care worldwide.
Profiles: Scopus | ORCID | LinkedIn
Featured Publications
Sriraman, S., Virtanen, V., Kukkula, A., Toriseva, M., Lumiainen, A., West, G., Poutanen, M., Taimen, P., & Sundvall, M. (2025). Androgen receptor‐mediated regulation of BRCA1 modulates the antioxidant defense in prostate cancer. The Journal of Pathology. Advance online publication.
Koskela, S., Pulkkinen, O., Mehmood, A., Kallionpää, R., Birkman, E.-M., Huuhtanen, J., Mustjoki, S., Coupland, S., Aittokallio, T., & Sundvall, M. (2025, July 8). Novel anti-PD1 predictive signature and functional dendritic-cell biomarkers in melanoma identified with systems immunology [Preprint]. Research Square.
Gnjatovic, J., Garces Ibanez, J., Rantala, J., Sundvall, M., Alanne, E., Vaittinen, S., Mattila, P., Jäättelä, M., & Hämälistö, S. (2025, April 29). Patient-derived lymphoma organoids and repurposed drugs: Novel solutions for improved B cell lymphoma treatment [Conference paper].
Hollmén, M., Löyttyniemi, E., Juhanoja, E., Vihinen, P., & Sundvall, M. (2025, February). High comorbidity and tumor proliferation predict survival of localized breast cancer patients after curative surgery: A retrospective analysis of real-world data in Finland. Surgical Oncology, 102(188).
Nissi, L., Tuominen, S., Routila, J., Huusko, T., Ketonen, P., Sundvall, M., Leivo, I., Irjala, H., Minn, H., & Grönroos, T. J. (2024, November). xCT as a predictor for survival in a population‐based cohort of head and neck squamous cell carcinoma. Cancer Medicine.